Valeant Pharmaceuticals Completes $2B Syndicated Secured Credit Facilities

Valeant Pharmaceuticals International, Inc., as borrower, entered into the Second Amended and Restated Credit and Guaranty Agreement (the “Credit Agreement”) with certain subsidiaries of Valeant, as guarantors. Goldman Sachs Lend-ing Partners LLC (“GSLP”) and J.P. Morgan Securities LLC, acted as joint lead arrangers and joint bookrunners. JPMorgan Chase Bank, N.A., acted as syndication agent and issuing bank. GSLP, acted as administrative agent and collateral agent.

Valeant's in-house team was led by Robert Chai-Onn, Executive Vice President, General Counsel and Corporate Secre-tary, and by Ling Zeng, Vice President, Business and Legal Affairs. Valeant was represented in Canada by Norton Rose OR LLP, with a team that included Gino Martel, Peter Wiazowski, Martin Theriault, Suzanna Lobo and Aimée Halfyard (banking and corporate) and Derek Chiasson (tax). Skadden, Arps, Slate, Meagher & Flom LLP represented Valeant in the United States, with a team that included Alexandra Margolis and Paul Laskow.

The joint lead arrangers and joint bookrunners were represented in Canada by Osler, Hoskin & Harcourt LLP, with a team that included Michael Hart and Ben Leith (banking); and in the United States by Cahill Gordon & Reindel LLP with a team that included Noah Newitz, Josiah Slotnick, Samir Ahuja and Daniel Tarnopol.